Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Dentsply Sirona's accounts receivables for the quarter that ended in Jun. 2026 was $620 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Dentsply Sirona's Days Sales Outstanding for the quarter that ended in Jun. 2026 was 63.00.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Dentsply Sirona's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was $-14.14.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Dentsply Sirona's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Dentsply Sirona's accounts receivable are only considered to be worth 75% of book value:
Dentsply Sirona's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Dentsply Sirona Accounts Receivable Related Terms
Dentsply Sirona Accounts Receivable Historical Data
* Premium members only.
The historical data trend for Dentsply Sirona's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dentsply Sirona (XRAY) has a Accounts Receivable of $620 Mil as of Jun. 2026. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Dentsply Sirona and its competitors.
Is Dentsply Sirona's Accounts Receivable too high?
Dentsply Sirona's current Accounts Receivable is $620 Mil. Overall, Dentsply Sirona has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Dentsply Sirona's Accounts Receivable compare to LMAT and WRBY?
Dentsply Sirona's Accounts Receivable of $620 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Medical Devices & Instruments company?
A good Accounts Receivable depends on the Medical Devices & Instruments industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Dentsply Sirona and its competitors. Dentsply Sirona's current Accounts Receivable is $620 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dentsply Sirona stock overvalued right now?
Based on GuruFocus' analysis, Dentsply Sirona (XRAY) is currently considered Possible Value Trap. The stock's GF Value™ is $17.35, compared to a current price of $10.90 — trading 37.2% below its estimated fair value. The current Accounts Receivable is $620 Mil. Dentsply Sirona's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Dentsply Sirona (XRAY), the current Accounts Receivable is $620 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dentsply Sirona (XRAY) Overvalued in 2026?
Based on GuruFocus' analysis, Dentsply Sirona stock appears to be undervalued.
The current stock price of $10.90 is trading 37.2% below its estimated GF Value™ of $17.35.
GuruFocus considers Dentsply Sirona to be Possible Value Trap.
Key valuation signals for XRAY:
Accounts Receivable: $620 Mil
GF Value™: $17.35 vs. price of $10.90 (37.2% below fair value)
No single metric tells the full story. See the XRAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
59GF Score
Get the complete analysis for XRAY
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XRAY has been successfully added to your 
